NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS England · Awarded

Buyer
NHS England
Status
Awarded
Country
United Kingdom
Region
England
Sector
Manufacturing
Reference
FaT-ocds-h6vhtk-04e273
Published
2025-07-29
Deadline
2026-04-18

Tender summary

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.

Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.

Register for full access

IT tenders · Construction tenders · Sitemap